{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T10:29:21Z","timestamp":1792405761354,"version":"4.4.0"},"reference-count":45,"publisher":"MDPI AG","issue":"8","license":[{"start":{"date-parts":[[2022,7,30]],"date-time":"2022-07-30T00:00:00Z","timestamp":1659139200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004488","name":"Croatian Science Foundation Grant \u201cMolecular diversity of Epstein\u2013Barr virus\u201d","doi-asserted-by":"publisher","award":["IP-2020-02-8961"],"award-info":[{"award-number":["IP-2020-02-8961"]}],"id":[{"id":"10.13039\/501100004488","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pathogens"],"abstract":"<jats:p>Epstein\u2013Barr virus (EBV) was discovered in 1964 in the cell line of Burkitt lymphoma and became first known human oncogenic virus. EBV belongs to the Herpesviridae family, and is present worldwide as it infects 95% of people. Infection with EBV usually happens during childhood when it remains asymptomatic; however, in adults, it can cause an acute infection known as infectious mononucleosis. In addition, EBV can cause wide range of tumors with origins in B lymphocytes, T lymphocytes, and NK cells. Its oncogenicity and wide distribution indicated the need for vaccine development. Research on mice and cultured cells as well as human clinical trials have been in progress for a few decades for both prophylactic and therapeutic EBV vaccines. The main targets of the vaccines are EBV envelope glycoproteins such as gp350 and EBV latent genes. The long wait for the EBV vaccine is due to the complexity of the EBV replication cycle and the wide range of its host cells. Although some strategies such as the use of dendritic cells and recombinant Vaccinia viral vectors have shown success, ongoing clinical trials using mRNA-based vaccines as well as new delivery systems as nanoparticles are yet to show the best choice of vaccine target and its production strategy.<\/jats:p>","DOI":"10.3390\/pathogens11080864","type":"journal-article","created":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T04:04:00Z","timestamp":1659326640000},"page":"864","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":25,"title":["Progress in Prophylactic and Therapeutic EBV Vaccine Development Based on Molecular Characteristics of EBV Target Antigens"],"prefix":"10.3390","volume":"11","author":[{"given":"Marija","family":"Rozman","sequence":"first","affiliation":[{"name":"Department of Immunological and Molecular Diagnostics, University Hospital for Infectious Diseases Zagreb, Zagreb 10000, Croatia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4783-2114","authenticated-orcid":false,"given":"Petra","family":"Kora\u0107","sequence":"additional","affiliation":[{"name":"Division of Biology, Faculty of Science, University of Zagreb, Zagreb 10000, Croatia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karlo","family":"Jambrosic","sequence":"additional","affiliation":[{"name":"Laboratory for Analytical Chemistry and Biogeochemistry of Organic Compounds, Division for Marine and Environmental Research, Ru\u0111er Bo\u0161kovi\u0107 Institute, Zagreb 10000, Croatia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9852-5806","authenticated-orcid":false,"given":"Snjezana","family":"\u017didovec Lepej","sequence":"additional","affiliation":[{"name":"Department of Immunological and Molecular Diagnostics, University Hospital for Infectious Diseases Zagreb, Zagreb 10000, Croatia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,7,30]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"867","DOI":"10.3389\/fcimb.2022.935205","article-title":"EBV Infection and Its Regulated Metabolic Reprogramming in Nasopharyngeal Tumorigenesis","volume":"12","author":"Yang","year":"2022","journal-title":"Front. Cell. Infect. Microbiol."},{"key":"ref_2","first-page":"1","article-title":"Targeting the signaling in Epstein\u2013Barr virus-associated diseases: Mechanism, regulation, and clinical study","volume":"6","author":"Cao","year":"2021","journal-title":"Signal Transduct Target Ther."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"734471","DOI":"10.3389\/fimmu.2021.734471","article-title":"Epstein Barr Virus: Development of Vaccines and Immune Cell Therapy for EBV-Associated Diseases","volume":"12","author":"Cui","year":"2021","journal-title":"Front. Immunol."},{"key":"ref_4","first-page":"133","article-title":"Epstein\u2013Barr virus and multiple sclerosis","volume":"23","author":"Yates","year":"2022","journal-title":"Nat. Rev. Neurosci."},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Shafiee, A., Aghajanian, S., Athar, M.M.T., and Gargari, O.K. (2022). Epstein\u2013Barr virus and COVID-19. J. Med. Virol., 4040\u20134042.","DOI":"10.1002\/jmv.27823"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"e29027","DOI":"10.1097\/MD.0000000000029027","article-title":"The effect of Epstein\u2013Barr virus viremia on the progression to severe COVID-19","volume":"101","author":"Im","year":"2022","journal-title":"Medicine"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"3147","DOI":"10.1128\/jvi.69.5.3147-3155.1995","article-title":"Structure and role of the terminal repeats of Epstein-Barr virus in processing and packaging of virion DNA","volume":"69","author":"Zimmermann","year":"1995","journal-title":"J. Virol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"13557","DOI":"10.1038\/ncomms13557","article-title":"Structural basis for Epstein-Barr virus host cell tropism mediated by gp42 and gHgL entry glycoproteins","volume":"7","author":"Sathiyamoorthy","year":"2016","journal-title":"Nat. Commun."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1128\/JVI.01410-15","article-title":"Epstein-Barr Virus (EBV) Tegument Protein BGLF2 Promotes EBV Reactivation through Activation of the p38 Mitogen-Activated Protein Kinase","volume":"90","author":"Liu","year":"2016","journal-title":"J. Virol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"9435","DOI":"10.1128\/JVI.00473-06","article-title":"Epstein-Barr Virus BNRF1 Protein Allows Efficient Transfer from the Endosomal Compartment to the Nucleus of Primary B Lymphocytes","volume":"80","author":"Feederle","year":"2006","journal-title":"J. Virol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"a013029","DOI":"10.1101\/cshperspect.a013029","article-title":"Replication of Epstein-Barr viral DNA","volume":"5","author":"Hammerschmidt","year":"2013","journal-title":"Cold Spring Harb. Perspect Biol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1093\/femsre\/fuz023","article-title":"Epithelial cell infection by Epstein-Barr virus","volume":"43","author":"Chen","year":"2019","journal-title":"FEMS Microbiol. Rev."},{"key":"ref_13","first-page":"164","article-title":"Ephrin receptor A2 is an epithelial cell receptor for Epstein-Barr virus entry","volume":"3","author":"Zhang","year":"2018","journal-title":"Nat. Microbiol."},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Wallaschek, N., Reuter, S., Silkenat, S., Wolf, K., Niklas, C., Kayisoglu, \u00d6., and Bartfeld, S. (2021). Ephrin receptor A2, the epithelial receptor for Epstein-Barr virus entry, is not available for efficient infection in human gastric organoids. PLoS Pathog., 17.","DOI":"10.1371\/journal.ppat.1009210"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"200227","DOI":"10.1016\/j.tvr.2021.200227","article-title":"Potential entry receptors for human \u03b3-herpesvirus into epithelial cells: A plausible therapeutic target for viral infections","volume":"12","author":"Rani","year":"2021","journal-title":"Tumour Virus Res."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"36614","DOI":"10.1074\/jbc.M706324200","article-title":"Isolating the Epstein-Barr Virus gp350\/220 Binding Site on Complement Receptor Type 2 (CR2\/CD21)","volume":"282","author":"Young","year":"2007","journal-title":"J. Biol. Chem."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"701611","DOI":"10.3389\/fmicb.2021.701611","article-title":"Main Targets of Interest for the Development of a Prophylactic or Therapeutic Epstein-Barr Virus Vaccine","volume":"12","author":"Lupo","year":"2021","journal-title":"Front. Microbiol."},{"key":"ref_18","first-page":"2175","article-title":"The Status and Prospects of Epstein\u2014Barr Virus Prophylactic Vaccine Development","volume":"12","author":"Sun","year":"2021","journal-title":"Front. Immunol."},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Cai, J., Zhang, B., Li, Y., Zhu, W., Akihisa, T., Li, W., and Zhang, J. (2021). Prophylactic and therapeutic ebv vaccines: Major scientific obstacles, historical progress, and future direction. Vaccines, 9.","DOI":"10.3390\/vaccines9111290"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1016\/j.virol.2007.09.012","article-title":"The Epstein\u2014Barr virus BMRF-2 protein facilitates virus attachment to oral epithelial cells","volume":"370","author":"Xiao","year":"2008","journal-title":"Virology"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1007\/978-1-4939-6655-4_12","article-title":"Terminal repeat analysis of EBV genomes","volume":"1532","author":"Koroknai","year":"2017","journal-title":"Methods Mol. Biol."},{"key":"ref_22","first-page":"138","article-title":"Epstein-Barr","volume":"47","author":"Perspectives","year":"2018","journal-title":"HHS Public Access"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"457","DOI":"10.3389\/fmicb.2016.00457","article-title":"Role of EBNA-3 Family Proteins in EBV Associated B-cell Lymphomagenesis","volume":"7","author":"Bhattacharjee","year":"2016","journal-title":"Front. Microbiol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"2852","DOI":"10.7150\/jca.25460","article-title":"The emerging role of Epstein-Barr virus encoded microRNAs in nasopharyngeal carcinoma","volume":"9","author":"Fan","year":"2018","journal-title":"J. Cancer"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/S0065-230X(10)07004-1","article-title":"Role of EBERs in the Pathogenesis of EBV Infection","volume":"107","author":"Iwakiri","year":"2010","journal-title":"Adv. Cancer Res."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1038\/s41467-021-27894-1","article-title":"The three-dimensional structure of Epstein-Barr virus genome varies by latency type and is regulated by PARP1 enzymatic activity","volume":"13","author":"Morgan","year":"2022","journal-title":"Nat. Commun."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"587380","DOI":"10.3389\/fimmu.2020.587380","article-title":"Epstein-Barr Virus and Systemic Autoimmune Diseases","volume":"11","author":"Houen","year":"2021","journal-title":"Front. Immunol."},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Murata, T., Sugimoto, A., Inagaki, T., Yanagi, Y., Watanabe, T., Sato, Y., and Kimura, H. (2021). Molecular basis of epstein\u2013barr virus latency establishment and lytic reactivation. Viruses, 13.","DOI":"10.3390\/v13122344"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"e131","DOI":"10.1038\/emm.2014.84","article-title":"Epstein\u2014Barr virus latent genes","volume":"47","author":"Kang","year":"2015","journal-title":"Exp. Mol. Med."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"e002516","DOI":"10.1136\/jitc-2021-002516","article-title":"Induction of EBV latent membrane specific T cells and construction of individualized TCR engineered T cells for EBV-associated malignancies","volume":"9","author":"Zhang","year":"2021","journal-title":"J. Immunother. Cancer"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1186\/s12985-017-0859-5","article-title":"A study of Epstein-Barr virus infection in the Chinese tree shrew(Tupaia belangeri chinensis)","volume":"14","author":"Wang","year":"2017","journal-title":"Virol. J."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"789604","DOI":"10.3389\/fimmu.2021.789604","article-title":"Tree Shrew Is a Suitable Animal Model for the Study of Epstein Barr Virus","volume":"12","author":"Xia","year":"2022","journal-title":"Front. Immunol."},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Kayesh, M.E.H., Sanada, T., Kohara, M., and Tsukiyama-Kohara, K. (2021). Tree shrew as an emerging small animal model for human viral infection: A recent overview. Viruses, 13.","DOI":"10.3390\/v13081641"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1053\/j.semdp.2017.04.003","article-title":"Human immunodeficiency virus (HIV) and Epstein-Barr virus (EBV) related lymphomas, pathology view point","volume":"34","author":"Fend","year":"2017","journal-title":"Semin. Diagn. Pathol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.ebiom.2018.12.041","article-title":"Epstein-Barr virus, malaria and endemic Burkitt lymphoma","volume":"39","author":"Velavan","year":"2019","journal-title":"EBioMedicine"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"e037505","DOI":"10.1136\/bmjopen-2020-037505","article-title":"Global and regional incidence, mortality and disability-adjusted life-years for Epstein-Barr virus-attributable malignancies, 1990\u20132017","volume":"10","author":"Khan","year":"2020","journal-title":"BMJ Open"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1128\/JVI.01409-07","article-title":"Phase I Trial of a CD8 \u03e9 T-Cell Peptide Epitope-Based Vaccine for Infectious Mononucleosis","volume":"82","author":"Elliott","year":"2008","journal-title":"J. Virol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1097\/TP.0b013e3181b9d918","article-title":"A Phase I Trial of Epstein-Barr Virus Gp350 Vaccine for Children With Chronic Kidney Disease Awaiting Transplantation","volume":"88","author":"Rees","year":"2009","journal-title":"Transplantation"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"eabf3685","DOI":"10.1126\/scitranslmed.abf3685","article-title":"A bivalent Epstein-Barr virus vaccine induces neutralizing antibodies that block infection and confer immunity in humanized mice","volume":"14","author":"Wei","year":"2022","journal-title":"Sci. Transl. Med."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1111\/1348-0421.12155","article-title":"Regulation of Epstein-Barr virus reactivation from latency","volume":"58","author":"Murata","year":"2014","journal-title":"Microbiol. Immunol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.2217\/fon.12.125","article-title":"Dendritic-cell based vaccines: Barriers and opportunities","volume":"8","author":"Cintolo","year":"2012","journal-title":"Future Oncol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1128\/JVI.78.2.768-778.2004","article-title":"Dual Stimulation of Epstein-Barr Virus (EBV) -Specific CD4 \u03e9- and CD8 \u03e9 -T-Cell Responses by a Chimeric Antigen Construct: Potential Therapeutic Vaccine for EBV-Positive Nasopharyngeal Carcinoma","volume":"78","author":"Taylor","year":"2004","journal-title":"J. Virol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"2735","DOI":"10.3390\/v6072735","article-title":"Modified vaccinia virus ankara (MVA) as production platform for vaccines against influenza and other viral respiratory Diseases","volume":"6","author":"Altenburg","year":"2014","journal-title":"Viruses"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"4315","DOI":"10.1007\/s00018-020-03538-3","article-title":"Vaccination against the Epstein\u2013Barr virus","volume":"77","author":"Leung","year":"2020","journal-title":"Cell Mol. Life Sci."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"11217","DOI":"10.1128\/JVI.01673-08","article-title":"Molecular Basis of the Interaction between Complement Receptor Type 2 (CR2\/CD21) and Epstein-Barr Virus Glycoprotein gp350","volume":"82","author":"Young","year":"2008","journal-title":"J. Virol."}],"container-title":["Pathogens"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-0817\/11\/8\/864\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T23:59:57Z","timestamp":1760140797000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-0817\/11\/8\/864"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,30]]},"references-count":45,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2022,8]]}},"alternative-id":["pathogens11080864"],"URL":"https:\/\/doi.org\/10.3390\/pathogens11080864","relation":{},"ISSN":["2076-0817"],"issn-type":[{"value":"2076-0817","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,30]]}}}